Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

Abstract

Pentraxin-3 vs. C-reactive protein and other prognostic biomarkers in acute coronary syndromes: A substudy of the PLATelet inhibition and patients Outcomes (PLATO) trial.

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

“…Of these, 19 relevant records were further excluded for the reasons given in Figure 1. Finally, 16 cohort studies were obtained for the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28).…”

“…Overall, 16 cohort studies including 11,007 adults with CAD were included in the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18).…”

“…Overall, 16 cohort studies including 11,007 adults with CAD were included in the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18). For the subtype of CAD, four studies included patients with stable CAD (13,17,19,20), while the other studies included patients with ACS [7 patients with STEMI (14, 21-25, 27), two patients with NSTE-ACS (16,18), and three patients with both STEMI and NSTE-ACS (15,26,28)].…”

Serum pentraxin‐3 follows a logarithmic distribution particularly at low expected levels

“…In studies with higher numbers of participants, healthy or with disease, it is the logarithmic distribution of serum PTX3 that made the researchers use logarithmic/exponential scales when reporting their data. [5][6][7] In the case of a small sample size and high expected serum PTX3 levels, it is depicted in Figure 3 how the data distribution may appear normal, particularly after excluding the extreme values (ie, the outliers), which is a common statistical practice. This was possibly the case in many previous studies.…”

“…This was possibly the case in many previous studies. [8][9][10][11] However, extreme values in a linear scale are an integral feature of a logarithmic/exponential distribution [5][6][7] and should not be missed.…”